FW
Therapeutic Areas
Arcutis Biotherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Topical Roflumilast Cream 0.3% (ZORYVE) | Plaque Psoriasis (Adults & Adolescents) | Approved |
| Topical Roflumilast Cream 0.3% | Plaque Psoriasis (Children 2-5 years) | sNDA Submitted |
| Topical Roflumilast Cream 0.15% (ZORYVE) | Atopic Dermatitis (Adults & Adolescents) | Approved |
| Topical Roflumilast Cream 0.05% | Atopic Dermatitis (Children 3-24 months) | Phase 2 |
| Topical Roflumilast Foam 0.3% (ZORYVE) | Seborrheic Dermatitis | Approved |
| Topical Roflumilast Foam 0.3% | Scalp and Body Psoriasis | Phase 3 Completed |
| ARQ-234 | Atopic Dermatitis | Preclinical/Phase 1 |
Leadership Team at Arcutis Biotherapeutics
TE
Todd Edwards
Chief Commercial Officer
PB
Patrick Burnett
Chief Medical Officer
DT
David Topper
Chief Financial Officer
DD
Derek DiRocco
Senior Vice President, Research & Development
SB
Scott Burrows
Chief Operating Officer and Chief Financial Officer (former)